SFI
CARM

Susquehanna Fundamental Investments’s Carisma Therapeutics CARM Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,264
Closed -$117K – 1712
2021
Q2 		$117K Sell
1,264
-1,606
-56% -$102K ﹤0.01% 1557
2021
Q1 		$149K Buy
+2,870
New +$135K ﹤0.01% 1428

Other funds holding CARM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Susquehanna Fundamental Investments's CARM Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Carisma Therapeutics (CARM) in Q3 2021, closing a stake of 1,264 shares — an estimated $117K sold.

Susquehanna Fundamental Investments first reported a position in CARM in Q1 2021 and held it in 2 quarters. The position peaked at $149K in Q1 2021. 103 funds tracked by Wall St. Rank hold CARM as of Q3 2021.

  • Susquehanna Fundamental Investments reported no remaining Carisma Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 1,264 Carisma Therapeutics shares in Q3 2021, an estimated $117K.
  • Susquehanna Fundamental Investments first reported a position in Carisma Therapeutics in Q1 2021 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Carisma Therapeutics position peaked at $149K in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.